Duloxetine in the Treatment of Women with Urinary Incontinence: A Systematic Review and Meta-analysis of Efficacy Data from Randomized Controlled Clinical Trials

dc.contributor.authorMangir, Naside
dc.contributor.authorUçar, Murat
dc.contributor.authorGülpınar, Ömer
dc.contributor.authorOzkurkcugil, Cüneyd
dc.contributor.authorDemirkesen, Oktay
dc.contributor.authorTarcan, Tufan
dc.date.accessioned2026-01-24T12:20:57Z
dc.date.available2026-01-24T12:20:57Z
dc.date.issued2023
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractDuloxetine is the only available agent for the medical treatment of stress urinary incontinence (SUI). In this systematic review, we analyzed the efficacy and safety of duloxetine treatment in women with SUI and stress-predominant mixed urinary incontinence (SPMUI). We searched the literature using OVID MEDLINE, Embase and ULAKBIM (Turkish database) databases for placebo-controlled studies on the use of duloxetine in women with SUI or SPMUI. Data on change in incontinence episode frequency (IEF), decrease in the number of continence pads used, increase in voiding interval (minute) and discontinuation rates due to adverse effects and lack of efficacy (%) were extracted. A total of 12 randomized controlled trials were included. Duloxetine treatment results in an 18% decrease in IEF and 16% decrease in the number of incontinence pads used compared to pre-treatment status. It also increases the time interval between the voids by 18 min. Duloxetine treatment was associated with higher treatment discontinuation rates compared with placebo. The reason for discontinuation was related to the side effects of the treatment rather than lack of efficacy. Duloxetine can be an effective treatment option in women with UI based on high-level evidence supporting its efficacy. Further studies with larger patient populations and longer durations of follow-up are required to assess its safety profile. © Copyright 2023 by the Association of Urological Surgery / Journal of Urological Surgery published by Galenos Publishing House.
dc.identifier.doi10.4274/jus.galenos.2022.2022.0027
dc.identifier.endpage8
dc.identifier.issue1
dc.identifier.scopus2-s2.0-105022143025
dc.identifier.scopusqualityN/A
dc.identifier.startpage1
dc.identifier.trdizinid1168187
dc.identifier.urihttps://doi.org/10.4274/jus.galenos.2022.2022.0027
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1168187
dc.identifier.urihttps://hdl.handle.net/20.500.12868/4727
dc.identifier.volume10
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherGalenos Publishing House
dc.relation.ispartofJournal of Urological Surgery
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_Scopus_20260121
dc.subjectduloxetine hydrochloride
dc.subjectmixed
dc.subjectstress
dc.subjectsystematic review
dc.subjecturinary incontinence
dc.subjectUrinary incontinence
dc.titleDuloxetine in the Treatment of Women with Urinary Incontinence: A Systematic Review and Meta-analysis of Efficacy Data from Randomized Controlled Clinical Trials
dc.typeReview Article

Dosyalar